Aptuit said today it has acquired Kuecept for an undisclosed price, in a deal the buyer said would help it meet customer demand for specialist drug preformulation, formulation prototyping, and formulation development services.
London-based Kuecept offers technical expertise in CRO services supporting preclinical drug development. Kuecept provides preformulation testing, preclinical dose-vehicle screening, and formulation development, as well as a broad range of drug-delivery technologies that include respiratory, parenteral, and oral formulation development for insoluble compounds.
In addition, Kuecept’s formulation rescue consultancy assists drug developers in moving APIs through IND/CTA, enabling safety assessment.
“The acquisition of Kuecept enhances our scientific expertise and capabilities in the preformulation development space,” Aptuit CEO Jonathan Goldman, M.D., MBBS, MBA, said in a statement. “The addition allows us to improve the transition of compounds from medicinal chemistry in discovery through to formal regulatory-based drug product development.”
He added that Kuecept's expertise will also further enhance Aptuit’s INDiGO® program, designed to accelerate early drug candidates into clinical development by reducing time from API to regulatory submission (IND/CTA) in as little as 26 weeks under certain circumstances.
“We expect our customers to benefit from improved solubility solutions, reduced drug attrition, and associated reductions in time and development costs,” Dr. Goldman said.
Kuecept CEO and founder Mark Saunders, Ph.D., added, “Through this acquisition, our customers can now combine our capabilities with Aptuit's full suite of integrated drug development solutions to facilitate the transition of new drugs through preclinical evaluation to clinical manufacture.”